
    
      PRIMARY OBJECTIVES:

      I. Explore the effectiveness of a menadione topical lotion to the face to prevent cutaneous
      and psychological discomfort from epidermal growth factor receptor (EGFR) inhibitors.

      SECONDARY OBJECTIVES:

      I. Explore the adverse event profile of a menadione topical lotion to the face to prevent
      rash from EGFR inhibitors.

      II. Explore whether rash or adverse events worsen over a 4 week period after this 4-week
      intervention.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients apply menadione topical lotion twice daily (BID) for 28 days.

      ARM II: Patients apply topical placebo lotion BID for 28 days.

      After completion of study treatment, patients are followed up for 4 weeks.
    
  